FGEN FibroGen
- 1.040
- +0.020+1.96%
- 1.010
- -0.030-2.88%
FibroGen News
Express News | FibroGen To Present Data From Dose Escalation Phase 1b Study of FG-3246 Plus Enzalutamide At 2024 American Society of Clinical Oncology Annual Meeting May 31-Jun. 4
Express News | FibroGen Announces Clinical Data From Dose Escalation Phase 1B Study of FG-3246 (for46) in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer Will Be Presented at the 2024 American Society of Clinical Oncology A
FibroGen Announces Clinical Data From Dose Escalation Phase 1b Study of FG-3246 (FOR46) In...
Express News | Kind Pharmaceuticals-Parties Agreed to Withdraw All Pending Legal Proceedings Between Them Regarding Hif-Phi Technology,Without Payment by Either Party
Express News | Kind Pharmaceuticals-Resolution of Dispute With FibroGen Was Regarding Co's Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Technology
Express News | Kind Pharmaceuticals-Hangzhou Andao Pharmaceutical, Co Announced a Resolution of Their Recent Dispute With FibroGen
Kind Pharmaceuticals Announces Settlement
HANGZHOU, China, April 16, 2024 /PRNewswire/ -- Today, Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC ("Kind Pharmaceuticals"), together with its Chief Executive Officer Dr. Dong Liu
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet
The FibroGen, Inc. (NASDAQ:FGEN) share price has softened a substantial 28% over the previous 30 days, handing back much of the gains the stock has made lately. For any long-term shareholders, the
FibroGen, Inc.'s (NASDAQ:FGEN) Latest 43% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Key Insights Institutions' substantial holdings in FibroGen implies that they have significant influence over the company's share price A total of 8 investors have a majority stake in the company wi
FibroGen Falls After Early-stage Data for Prostate Cancer Drug
Express News | FibroGen Shares Are Trading Lower After the Company Announced Topline Results From the Phase 1 Monotherapy Study of FG-3246 in Patients With Metastatic Castration-resistant Prostate Cancer
Top Midday Decliners
View (VIEW) said late Tuesday that it received approval from key shareholders for a balance sheet restructuring plan. Shares slumped about 60%, with intraday trading volume at over 1.1 million versus
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersARCA biopharma (NASDAQ:ABIO) shares moved upwards by 84.8% to $3.16 during Wednesday's regular session. The market value of their outstanding shares is at $45.8 million. Kintara Therapeutics (N
FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape
FibroGen Inc (NASDAQ:FGEN) announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (A
FibroGen, Acorda Therapeutics, Enveric Biosciences Among Healthcare Movers
FibroGen Says Phase 1 Study of Potential Prostate Cancer Treatment Shows Promise
FibroGen (FGEN) said late Tuesday it saw "encouraging" data from a Fortis Therapeutics-sponsored phase 1 study of FG-3246 for patients with metastatic castration-resistant prostate cancer whose tumors
FibroGen (FGEN) Gets a Sell From Goldman Sachs
FibroGen Reports Data From Fortis Therapeutics-Sponsored Phase 1 Study Of FG-3246
In the efficacy analysis, PSA reductions of ≥ 50% were observed in 36% of PSA evaluable patients. For RECIST evaluable patients, 20% met the criteria of a partial response, or tumor reduction in size
Analysis
Price Target
No Data
